Social services in diabetes mellitus
Authors:
Andrea Bukovská 1,2
Authors‘ workplace:
Nemocničná lekáreň UN Martin
1; Diabetologické edukačné centrum I. internej kliniky JLF UK a UN Martin
2
Published in:
Diab Obez 2023; 23(45): 34-36
Category:
Reviews
Overview
Diabetes mellitus is a chronic, metabolic, non-communicable, incurable and serious disease in the 21st century. In addition to health, it also causes economic, psychological, social and societal consequences. Compensating for the social consequences of severe disability and providing appropriate social services effectively improves the quality of life of many diabetics of all ages.
Keywords:
diabetes mellitus – social consequences – social services
Sources
1. Bukovská A, Galajda P, Mokáň M. Edukácia a sociálne poradenstvo v diabetológii. P+M: Turany 2014. ISBN 978–80–89694–04–4.
2. Černá K, Bukovská A, Macko M. Praktický sprievodca dospelých diabetikov. m-edu: Žilina 2021. ISBN 978–80–973843–6–4.
3. Mokáň M, Martinka E, Galajda P et al. Diabetes mellitus a vybrané metabolické ochorenia. P+M: Martin 2008. ISBN 978–80–969713–9–8.
4. Zákon č. 448/2008 Z. z. o sociálnych službách a o zmene a doplnení zákona č. 455/1991 Zb. o živnostenskom podnikaní v znení neskorších predpisov. Dostupné z WWW: <https://www.szcoportal.sk/33/448–2008-z-z-zakon-o-socialnych-sluzbach-a-o-zmene-adoplneni-zakona-c-455–1991-zb-o-zivnostenskom-podnikani-zivnostensky-zakon-v-zneni-neskorsich-predpisov-v-zneni-cinnom-k-1–1-uniqueidOhwOuzC33qd2W4_6TwF4qJbGzHFqhOE-71Ti7xrGRqymVdaLTRYHmJQ/>.
Labels
Diabetology ObesitologyArticle was published in
Diabetes and obesity
2023 Issue 45
-
All articles in this issue
- Quo vadis, slovenská diabetológia?
- The dual GIP and GLP1 receptor agonist tirzepatide: a new effective treatment for type 2 diabetes mellitus
- Diabetes mellitus and options for early prevention of heart failure
- Evaluation of the current situation and possibilities in the management of obesity in Slovakia
- Ceramides and cardiovascular disease
- Social services in diabetes mellitus
- Practical experience with dapagliflozin: case reports
- The patient with type 2 diabetes is hemodynamically and metabolically stable, despite treatment, the progression of chronic kidney disease proceeds. What other options do we have? A case report
- Empagliflozin in patients with chronic kidney disease: results of the EMPA-KIDNEY trial and implications for clinical practice
- The head-to-head comparison of insulin glargine 300 units/ml and degludec 100 units/ml using the CGM technology: results of the InRange trial
- New indication criteria: better availability of GLP1 receptor agonists for our patients
- The SGLT2 inhibitor canagliflozin: benefits in the treatment of type 2 diabetes mellitus
- Spomienka na MUDr. Blaženu Dyskovú
- A glimpse into the 13th chamber – overt and covert manifestations of diabetes mellitus
- World Diabetes Congress, Lisabon 2022
- Advanced Technologies & Treatments for Diabetes 2023, Berlín
- 5th National SDS Symposium: How are we doing with technology in diabetology in Slovakia and what new things do we expect in the future?
- Diabetes and obesity
- Journal archive
- Current issue
- About the journal
Most read in this issue
- The dual GIP and GLP1 receptor agonist tirzepatide: a new effective treatment for type 2 diabetes mellitus
- Evaluation of the current situation and possibilities in the management of obesity in Slovakia
- Practical experience with dapagliflozin: case reports
- Diabetes mellitus and options for early prevention of heart failure